Explore the challenges presented by patient adherence in cardiovascular medicine, and the proven strategies effective in improving adherence rates, including the use of easily-accessible digital tools.
An overview of the evidence and the current recommendations in terms of MHT's role in preventing cardiovascular disease will be discussed as well as its safety in women with pre-existing cardiovascular disease.
In this Product Explainer, Dr. Robert Hungerford, GP with a special interest in ASCVD, heart failure and diabetes, explains the role of Semaglutide 2.4mg in weight management and cardiovascular risk reduction in secondary prevention.
This is your last chance to secure discounted registration to both national seminars before prices increase on Monday! You're invited to attend Australia's most popular seminars for GPs and healthcare professionals.